#2 - A biomaterial-based vaccine

06/02/22 • 23 min

In this 2nd episode, our co-hosts discuss the use of a macro-scale material to co-deliver GMCSF and CpG, both APC stimulating agents, as well as AML antigens to kill AML cells.
GUEST: Alex Najibi is now a postdoctoral fellow at Harvard School of Engineering and Applied Sciences, studying bioengineering in David Mooney's lab.
Original study => https://pubmed.ncbi.nlm.nih.gov/31937942/

Support the show

Thanks for listening! Let’s stay in touch:

Tweet us at @ImmunoTalks
Share our episodes on LinkedIN and Instagram
Email us at [email protected]

Send us a text

Support the show

Thanks for listening! Let’s stay in touch:

Tweet us at @ImmunoTalks
Share our episodes on LinkedIN and Instagram
Email us at [email protected]

Previous Episode

#1- Hooked on immunotherapy

Send us a text

In this first episode, our co-hosts talk about their background in immunology and what led them to it.
GUEST: Ed Fritsch. PhD, presidential fellow at the Dana-Farber, co-author of "Molecular Cloning: A Laboratory Manual", and co-founder of ACIR.

Support the show

Thanks for listening! Let’s stay in touch:

Tweet us at @ImmunoTalks
Share our episodes on LinkedIN and Instagram
Email us at [email protected]

Immunotherapy Talks with ACIR - #2 - A biomaterial-based vaccine

Transcript

Episode #2- A biomaterial-based vaccine

[00:00:00] Ute Burkhardt: Welcome to Immunotherapy Talks with ACIR. Reading research can be complicated, but it doesn't have to be. ACIR digests the latest in cancer immunotherapy research into bite-sized pieces to help you stay on top of the. I'm Ute Burkhardt,

[00:00:22] Nathan Suek: And I am Nathan Suek in this podcast, we'll discuss important and current questions in cancer immunology and